NCT07204275View on ClinicalTrials.gov

A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

October 6, 2025

Primary Completion Date

December 29, 2028

Study Completion Date

December 29, 2028

Conditions
Primary Membranous Nephropathy
Interventions
DRUG

Povetacicept

Solution for Subcutaneous Injection.

DRUG

Tacrolimus

Tablets for Oral Administration.

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT07204275 - A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) | Biotech Hunter | Biotech Hunter